Background/Aim: The new immunosuppressant SDZ RAD, a rapamycin derivative, inhibits growth factor driven cell proliferation. SDZ RAD designed for transplantation may also be a candidate agent to treat inflammatory kidney diseases. Therefore, we investigated the effects of SDZ RAD in two different animal models of glomerulonephritis, in anti- Thy1.1 nephritis and in acute puromycin aminonucleoside (PAN) nephrosis. Methods: Eighty-seven male Wistar rats were investigated. Anti-Thy1.1 nephritis: healthy rats (n = 9), SDZ RAD-treated healthy rats (n = 6), nephritic rats (n = 9), SDZ RAD placebo treated nephritic rats (n = 6), SDZ RAD-pretreated nephritic rats (n = 9), and early (n = 6) as well as delayed (n = 6) SDZ RAD-posttreated nephritic rats. PAN nephrosis: healthy rats (n = 6), SDZ RAD-treated healthy rats (n = 6), nephritic rats (n = 12), and SDZ RAD-pretreated nephritic rats (n = 12). In a separate study, 12 male Sprague-Dawley rats were analyzed in anti-Thy1.1 nephritis: healthy rats (n = 3), nephritic rats (n = 3) and pretreated nephritic rats (n = 6). SDZ RAD and SDZ RAD placebo were given at single doses of 2.5 mg/kg body weight per day by gavage. The experiments lasted until days +2 and +9 after induction of anti-Thy1.1 nephritis and until day +13 in the case of PAN nephrosis. Results: In anti-Thy1.1 nephritis, SDZ RAD demonstrated marked proinflammatory effects in a time-dependent manner, as reflected by severe focal damage to glomerular histology including inhibition of mesangial cell proliferation, reduction of creatinine clearance, and increase in plasma creatinine levels as well as proteinuria. Almost identical results were obtained in both rat strains. In contrary, SDZ RAD ameliorated significantly the development of PAN nephrosis. Animals pretreated by this agent showed a significant reduction of proteinuria and of glomerular invasion of monocytes/macrophages. Conclusion: Some caution is warranted for the use of SDZ RAD in inflammatory glomerular diseases, since it accentuated glomerular damage induced by anti-Thy1.1 antibodies.

Keywords:
Anti-Thy1.1 nephritis, Mesangial proliferative glomerulonephritis, PAN nephrosis, Glomerulonephritis, SDZ RAD, Rapamycin
1.
Schuler W, Sedrani R, Cottens S, Häberlin B, Schulz M, Schuurman H-J, Zenke G, Zerwes H-G, Schreier M: SDZ RAD: A new rapamycin derivative. Transplantation 1997;64:36–42.
2.
Schuurmann H-J, Cottens S, Fuchs S, Joergensen J, Meerloo T, Sedrani R, Tanner M, Zenke G, Schuler W: SDZ RAD: A new rapamycin derivative. Transplantation 1997;64:32–35.
3.
Morice WG, Brunn GJ, Wiederrecht G, Siekierka JJ, Abraham RT: Rapamycin-induced inhibition of p34cdc2 kinase activation is associated with G1/S-phase growth arrest in T lymphocytes. J Biol Chem 1993;268:3734–3738.
4.
Sehgal SN: Rapamune (sirolimus, rapamycin): An overview and mechanism of action. Ther Drug Monit 1995;17:660–665.
5.
Hatfield SM, Mynderse JS, Roehm NW: Rapamycin and FK506 differentially inhibit mast cell cytokine production and cytokine-induced proliferation and act as reciprocal antagonists. J Pharmacol Exp Ther 1992;261:970–976.
6.
Hultsch T, Martin R, Hohman RJ: The effects of the immunophilin ligands rapamycin and FK506 on proliferation of mast cells and other hematopoietic cell lines. Mol Biol Cell 1992;3:981–987.
7.
Akselband Y, Harding MW, Nelson PA: Rapamycin inhibits spontaneous and fibroblast growth factor β-stimulated proliferation of endothelial cells and fibroblasts. Transplant Proc 1991;23:2833–2836.
8.
Johnson RJ, Iida H, Alpers CE, Majeski MW, Schwartz SM, Pritzl P, Gordon K, Gown AM: Expression of smooth muscle cell phenotype by rat mesangial cells in immune complex nephritis: Alpha-smooth muscle actin is a marker of mesangial cell proliferation. J Clin Invest 1991;87:847–858.
9.
Steinmann-Niggli K, Ziswiler R, Küng M, Marti H-P: Inhibition of matrix metalloproteinases attenuates anti-Thy1.1 nephritis. J Am Soc Nephrol 1998;9:397–407.
10.
Eitner F, Westerhuis R, Burg M, Weinhold B, Gröne H-J, Ostendorf T, Rüthner U, Koch K-M, Rees A, Floege J: Role of interleukin-6 in mediating mesangial cell proliferation and matrix production in vivo. Kidney Int 1997;51:69–78.
11.
Ziswiler R, Daniel C, Kappeler A, Steinmann-Niggli K, Marti H-P: Mycophenolic acid: A new approach to the therapy of mesangial proliferative glomerulonephritis. J Am Soc Nephrol 1998;9:2055–2066.
12.
Jones CL, Buch S, Post M, McCulloch L, Liu E, Eddy AA: Renal extracellular matrix accumulation in acute puromycin aminonucleoside nephrosis in rats. Am J Pathol 1992;141:1381–1396.
13.
Gibaldi M, Perrier D: Appendix D; in Swarbrick J (ed): Pharmacokinetics. New York, Dekker, 1982, pp 445–449.
14.
Kirschfink M, Fritze H, Roelcke D: Complement activation by cold agglutinins. Vox Sang 1992;63:220–226.
15.
Süsal C, Kirschfink M, Kröpelin M, Daniel V, Opelz G: Complement activation by recombinant HIV-1 glycoprotein gp120. J Immunol 1994;152:6028–6034.
16.
Bagchus WM, Hoedemaeker PJ, Rozing J, Bakker WW: Glomerulonephritis induced by monoclonal anti-Thy1.1 antibodies: A sequential histological and ultrastructural study in the rat. Lab Invest 1986;55:680–687.
17.
Floege J, Johnson RJ, Gordon K, Iida H, Pritzl P, Yoshimura A, Campbell C, Alpers CE, Couser WG: Increased synthesis of extracellular matrix in mesangial proliferative nephritis. Kidney Int 1991;40:477–488.
18.
Floege J, Eng E, Lindner V, Alpers CE, Young BA, Reidy MA, Johnson RJ: Rat glomerular mesangial cells synthesize basic fibroblast growth factor. J Clin Invest 1992;90:2362–2369.
19.
Herrmann P, Poschmann G, Bolliger S, Meyer D, Schuurmann HJ: Mercuric chloride-induced glomerulopathy in BN rats: Application to preclinical drug testing. Transplant Proc 1993;25:2826–2827.
20.
Carlson RP, Hartmann DA, Tomchek LA, Walter TL, Lugay JR, Calhoun W, Sehgal SN, Chang JY: Rapamycin: A potential disease-modifying antiarthritic drug. J Pharmacol Exp Ther 1993;266:1125–1138.
21.
Kulkarni PS: Steroidal and nonsteroidal drugs in endotoxin-induced uveitis. J Ocul Pharmacol 1994;10:329–334.
22.
Francischi JN, Conroy DM, Cloutier S, Sirois P: Reduction of Sephadex-induced lung inflammation and bronchial hyperreactivity by rapamycin. Braz J Med Biol Res 1993;26:1105–1110.
23.
Marti H-P, Lee L, Kashgarian M, Lovett DH: Transforming growth factor-β1 stimulates glomerular mesangial cell synthesis of the 72-kd type IV collagenase. Am J Pathol 1994;144:82–94.
24.
Lovett DH, Johnson RJ, Marti H-P, Martin J, Davies M, Couser WG: Structural characterization of the mesangial cell type IV collagenase and enhanced expression in a model of immune complex-mediated glomerulonephritis. Am J Pathol 1992;141:85–98.
25.
Yamamoto T, Wilson CB: Quantitative and qualitative studies of antibody-induced mesangial cell damage in the rat. Kidney Int 1987;32:514–525.
26.
Renders L, Goppelt-Strübe M, Hauser IA: The sirolimus derivative SDZ-RAD inhibits rat and human mesangial cell proliferation (abstract). J Am Soc Nephrol 1998;9:508.
27.
Park Y-S, Guijarro C, Kim Y, Massay ZA, Kasiske BL, Keane WF, O’Donnell MP: Lovastatin reduces glomerular macrophage influx and expression of monocyte chemoattractant protein-1 mRNA in nephrotic rats. Am J Kidney Dis 1998;31:190–194.
© 2000 S. Karger AG, Basel
2000
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.